Cancer cells harboring mutant KRAS (e.g., MDA-MB-231) possess lower ASNS expression levels, leading to lower baseline aspartate levels explaining the rationale for the lack of aspartate detection in MDA-MB-231 lines [45]. This evidence concerns the gene KRAS and cancer.